Company / Cash & Equivalents
PURE BIOSCIENCE, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$334.0K
FY2025
5-year range
$334.0K / $3.4M
FY2021-FY2025
Trend
-4.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $3M in FY2022 to $334,000 in FY2025.
Based on SEC 10-K filings.
$334,000 in FY2025 with a 5-year CAGR of -38.6%.
Declined from $1M to $334,000 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -53.8%
- 5-Year CAGR
- -38.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- PURE BIOSCIENCE, INC.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -38.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 4.3% year-over-year.
- Peak cash & equivalents was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -116.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $334.0K | -4.3% |
| FY2024 | $349.0K | -68.1% |
| FY2023 | $1.1M | -67.7% |
| FY2022 | $3.4M | +41.9% |
| FY2021 | $2.4M | -37.7% |
| FY2020 | $3.8M | +864.6% |
| FY2019 | $398.0K | -53.2% |
| FY2018 | $851.0K | -48.1% |
| FY2017 | $1.6M | -68.4% |
| FY2016 | $5.2M | +293.2% |
As of FY2025 · SEC Form 10-K · Last checked Jun 29, 2026